Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Dyne Therapeutics, Inc. · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

During the period ended June 30, 2026, there have been no material changes in our market risk or how our market risk is managed from that described in “Quantitative and Qualitative Disclosures About Market Risk,” included in our Annual Report on Form 10-K filed with the SEC on March 2, 2026.